Biotech & Longevity · Saturday, 12 September 2026

01 Briefing what happened

The US regulator cleared a lung cancer pill for untreated patients, on 69 people and no comparison group

Biotech & Longevity 22 sources

Sevabertinib was already allowed for lung cancer that had grown through other treatment. On 9 September the US drug regulator allowed it as the first treatment, on a single-arm trial of 69 patients in which 75% of tumours shrank.

patients the lung cancer decision rests on

all of them received the drug; the trial had no comparison group [1]

75%

of those 69 whose tumours shrank

38% of the responses were still going a year later [1]

brand-new medicines cleared by the US regulator in 2026

the 38th was AstraZeneca's breast cancer pill, on 4 September [2]

The lead story — what happened

The US drug regulator cleared the lung cancer pill sevabertinib on 9 September for people who have had no treatment for the disease at all. [1]
The same pill was already cleared for people whose lung cancer had grown through an earlier treatment, so the medicine has not changed, only the moment it is given. [1]
It is for a narrow group: people whose tumour carries a fault in a gene called HER2, found by a test the regulator has authorised. [1]
The evidence is 69 patients. All of them got the drug, and there was nobody in the trial receiving anything else for comparison. [1]
Tumours shrank in 75% of those 69. Of the people who responded, 73% were still responding after six months and 38% after a year. [1]
This is an accelerated approval, the faster route the regulator uses when tumours shrinking looks strong enough to act on before anyone knows about survival. [1]
Nobody has shown that people given this pill first live longer than people given it after something else. [1]
Bayer, the German company that sells it as Hyrnuo, had the same application read at the same time by Britain's medicines regulator under a scheme called Project Orbis. The British decision has not come. [1]
The label warns of diarrhoea, liver damage, lung inflammation, weakened heart pumping, eye problems and raised pancreatic enzymes. [1]
The dose is 20mg twice a day with food, taken until the cancer grows or the side effects become intolerable. [1]
The regulator has cleared 38 brand-new medicines so far in 2026, and this is not one of them. It is a widening of a drug already on the market. [2]

Who is involved

Bayer

a German drug and chemicals company, one of the oldest in the industry; it makes sevabertinib and sells it as Hyrnuo
The FDA

the US drug regulator, which decides what may be sold to American patients; it granted the approval on 9 September
The MHRA

Britain's medicines regulator; it read the same application alongside the US one and has not yet decided
AstraZeneca

a British-Swedish drug company; its breast cancer pill was cleared five days earlier on a similar move-it-earlier idea

How it unfolded

Before sevabertinib is allowed only for lung cancer that has already grown through another treatment [1]
4 Sep the regulator clears AstraZeneca's Etcamah, the 38th brand-new medicine of 2026 [2]
9 Sep the same lung pill is cleared for patients who have had no treatment at all [1]
11 Sep Etcamah's label is published carrying a boxed warning about heart rhythm [3]
Next AstraZeneca's approval may depend on a confirmatory trial showing a real benefit [3]

Where this points

Watch AstraZeneca's Serena-4 trial, due to report before the end of the year, which tests the same breast cancer pill as a first treatment rather than as a switch. [4]

What is pushing on the whole day

The bar and the word are our reading of how hard each one is pushing today. The arrow is where it is heading. The evidence is in the stories below.

Approving on smaller proof High↑

The US regulator cleared Bayer's lung pill on 69 patients with nobody to compare them against. [1] It cleared AstraZeneca's breast cancer pill on how long patients went before a scan showed growth, counted from a blood test result. [3]

Testing before symptoms appear Building↑

AstraZeneca's pill is prescribed the moment a blood test finds an ESR1 mutation, before any scan changes. [4] A separate team reported that a protein called fibronectin breaks the brain's protective lining early in Alzheimer's, before memory goes. [6]

Computers designing the molecules Building↑

One team screened 1,758 computer-designed proteins as receptors for cancer-killing cells and found three reasons most of them fail. [13] Another released an open platform that predicts where a brain tumour will grow back, covering 79.4% of recurrences. [14]

Buying the laboratory suppliers Steady→

Revvity agreed to buy Human Cell Design, a French firm that grows human pancreas cells for laboratories. [9] The ten largest firms that manufacture medicines for other companies took $35.116bn in 2025. [12]

The rest of the day

21 more stories on this beat.

Each with its own sources. None of these is a link to the story above.

02
A boxed warning on last week's breast pill

The prescribing label for Etcamah, AstraZeneca's new breast cancer pill, was published on 11 September with a warning in a black box at the top. [3] Taken with ribociclib, one of the three drugs it is meant to be combined with, it can set off a dangerous heart rhythm and cause sudden death. Doctors must run a heart tracing before starting and keep checking it. The pill was cleared on 4 September as the 38th brand-new medicine of 2026. [2]

Why it matters — The regulator and its own outside advisers had both reviewed the trial negatively before AstraZeneca supplied more data. [4] The label now attaches a heart risk to a pill meant for patients whose cancer is still under control.
03
Novartis shareholders turn on its shopping

Eight shareholders in Novartis, a Swiss drugmaker and one of the world's largest, said they will press the company over the firms it has been buying. [5] The trigger was del-desiran, a drug for the muscle-wasting disease myotonic dystrophy, which missed the main goal of its final trial. [5] The shareholders said it raised questions about the $12bn Novartis paid last year for Avidity Biosciences, the company that had been developing it. The shares fell 11% in a day, wiping nearly $30bn and every gain made since January. [5]

Why it matters — It is the company's second big trial setback in days, and buying a late-stage drug is how large drugmakers normally replace the ones going off patent. [5]
04
Nine in ten costly biologics have no copy coming

Ninety per cent of the expensive biological medicines that lose patent protection by 2034 have no lower-cost version in development, according to a report cited by the Wall Street Journal. [5] Biological medicines are grown in living cells rather than mixed from chemicals, which makes copying them slow and costly. Those copies, called biosimilars, are what is meant to bring the price down once a patent runs out. [5]

Why it matters — Health systems budget for prices falling when patents expire. On these drugs there will be nothing to fall to. [5]
05
Chemotherapy's mark in children's healthy organs

Researchers read single DNA molecules from healthy tissue in children who had been treated for cancer. [18] They found that platinum chemotherapy, one of the oldest and most used families of cancer drug, pushed mutation levels in normal tissues up to those usually seen in adults. In the liver it left a pattern of damage found in no other organ. Some of the new mutations were of a type linked to leukaemia. [18]

Why it matters — Childhood cancer survivors often develop other illnesses decades later, and this is a first look at the record the treatment writes into organs it was never aimed at. [18]
06
Tablets did as well as drips for child pneumonia

A trial across South Africa, Uganda, Zambia, Zimbabwe and Mozambique put 1,101 children aged two months to six years on an injected antibiotic for severe pneumonia, then switched some of them to amoxicillin tablets. [20] World Health Organization guidance says five days of injections, which usually means five days in hospital. Readmission or death within 28 days was 5.6% on plain amoxicillin, 6.9% on amoxicillin-clavulanate and 6.3% on injections alone. [20]

Why it matters — Pneumonia is one of the leading infectious killers of young children, and a shorter stay means less exposure to the resistant bacteria that live in hospitals. [20]
07
A protein that leaks the brain's barrier

The blood-brain barrier is the tight lining that keeps most of what is in the blood out of the brain, and it starts leaking early in Alzheimer's disease. [6] The leak is worst in people carrying the APOE4 version of a common gene. A team reported on 11 September that a protein called fibronectin, made by support cells in the brain, piles up around the vessels and causes it. Removing the fibronectin restored the barrier in laboratory models and in animals. [6]

Why it matters — Today's Alzheimer's drugs attack the plaques and tangles that appear later. This points at a step that happens before them. [6]
08
Cancer-killing T cells grown from cord blood

T cell treatments are usually built from a patient's own immune cells, which takes weeks and costs six figures. [8] Cells from a donor can be made in advance and frozen, but they often attack the patient's own tissue. A UCLA team instead put a cancer-recognising receptor into blood stem cells from donated umbilical cord blood and grew them into T cells in the laboratory, so the dangerous receptors never form. One dose controlled ovarian cancer and melanoma in mice. [8]

Why it matters — It is an attempt to turn a made-to-order treatment into something frozen on a shelf. It has not been tried in a person. [8]
09
DNA hairpins to lower cholesterol

PCSK9 is a protein that strips away the receptors liver cells use to pull cholesterol out of the blood, so blocking it lowers cholesterol. [7] Researchers at the University of Barcelona and the University of Oregon designed short folded pieces of DNA, called polypurine hairpins, that turn the PCSK9 gene down at source. Their best one cut the protein by 87% in human liver cells and cholesterol by 47% in mice after a single injection. [7]

Why it matters — The PCSK9 drugs already on sale are antibodies or RNA and are expensive to manufacture. This is a cheaper kind of molecule doing the same job, so far only in cells and animals. [7]
10
1,758 designed proteins tested as receptors

AI can now design a protein to stick to almost any target, and the open question is whether those designs survive inside a medicine. [13] A team built 1,758 newly designed binders against three proteins found on blood cancers into the receptor a CAR T cell uses to spot its target. Most failed for three reasons: the cell switched itself on with no target there, the binder could not reach the part it was aimed at, or it stuck to the wrong things. [13]

Why it matters — It puts a number on the distance between designing a protein and having a treatment, which is the step usually skipped when AI-designed drugs are described. [13]
11
A free tool for where a brain tumour returns

Glioblastoma, the most aggressive common brain tumour in adults, almost always grows back, because its cells spread past the edge a scan can see. [14] Radiotherapy guidelines deal with that by treating a fixed margin around the visible tumour, the same width for everybody. A team released PREDICT-GBM, an open set of scans from 243 patients followed over time with a shared way of testing prediction models. Their own model covered 79.4% of the places the tumour actually came back. [14]

Why it matters — The gain over the standard margin was small but real, and publishing the patients means rival models can now be judged on the same cases. [14]
12
The barrier to personal cancer vaccines is the factory

A personalised messenger-RNA cancer vaccine is made from the mutations in one person's own tumour, so every dose is its own production run. [15] Making them at scale means thousands of patient-specific batches running side by side, which is the opposite of how medicines are normally mass-produced. The field moved forward last month when Merck and Moderna's personalised melanoma shot met its goal in a final-stage trial. [15]

Why it matters — The science question is being answered and the manufacturing question is not, and the second one decides how many people can ever be given it. [15]
13
Editing the marks on DNA, not the DNA

The epigenome is the set of chemical tags sitting on top of DNA that tell each cell which genes to use, and it shifts with stress, diet, infection, pollution and age. [16] Epigenome editing aims to change those tags rather than rewrite the genetic code underneath. Fyodor Urnov of the Innovative Genomics Institute at Berkeley co-founded Tune Therapeutics, which is running trials of an epigenome editing treatment for long-term hepatitis B in the liver. [16]

Why it matters — A change to the tags can in principle be undone, where a cut to the DNA cannot, and that difference decides what is safe to try. [16]
14
Where a flesh-destroying skin disease can take hold

Buruli ulcer is a bacterial disease that eats away skin and soft tissue, and it is common in parts of West and Central Africa. Nobody knows how the bacterium reaches people. [20] Researchers combined 110 environmental, ecological and social measurements with records of where the bacterium and the disease turn up. Seasonal swings in ultraviolet light and in temperature were the strongest predictors of cases. They published maps of where conditions would suit it worldwide. [20]

Why it matters — The maps point at places where the disease may already exist and go unreported, which is where surveillance would find it. [20]
15
The US regulator fills four leadership jobs

The Trump administration made four senior appointments at the US Food and Drug Administration permanent on 8 September. [22] Michael Davis, a psychiatrist, will direct the centre that reviews drugs. Karim Mikhail, formerly of Merck, will direct the centre that reviews biological medicines. Bret Koplow, an agency lawyer since 2011, takes the tobacco centre. Three of them had been doing the jobs in an acting capacity. Heidi Overton was nominated to run the whole agency late last month. [22]

Why it matters — These are the offices that decide which medicines reach patients, and they had been run by stand-ins. [22]
16
Revvity to buy a French pancreas cell maker

Revvity, an American maker of laboratory instruments and reagents, agreed to buy Human Cell Design, a French company that grows human pancreas beta cells for research. [9] Beta cells are the ones that make insulin. Laboratory-grown human versions let a company test a diabetes or obesity drug on human tissue before it reaches an animal or a person. The deal is expected to close in the last quarter of 2026. [9]

Why it matters — Testing on human cells rather than mouse cells is meant to catch failures earlier, and the tools for doing it are being bought up by the big instrument firms. [9]
17
A software firm starts its own drug company

Schrodinger sells software that predicts how a molecule will behave before anyone makes it, and it also takes stakes in the drugs its software helps design. [10] It has now spun out a new company, Tectora Therapeutics, handing it two small-molecule programmes, SDGR-4594 and SDGR-8139, whose targets have not been disclosed. Tectora will work in secret for now. Schrodinger's head of therapeutics research said it means to keep expanding arrangements like this. [10]

Why it matters — It is a toolmaker taking a share of the medicine rather than a fee for the tool, which changes what the software is worth to its owner. [10]
18
A testing lab buys the team that reads its data

Clean Cells, a French laboratory that checks medicines grown in living cells for stray viruses, launched a sequencing-based version of that test and bought Xegen, the French firm that had been analysing the results. [11] Sequencing produces enormous files, and turning them into an answer a regulator will accept is the hard part. Xegen's chief executive and his two staff are joining. European rules have been pushing this kind of testing since 2024. [11]

Why it matters — Reading the data was the step being contracted out, and it is the step the regulator's question actually turns on. [11]
19
Medicine factories-for-hire took $35bn

Most drugmakers no longer own all the factories that make their products. They hire firms called contract development and manufacturing organisations instead. [12] The ten largest took a combined $35.116bn in 2025, up 6% from $33.127bn the year before, and eight of the ten grew. Most large drug companies expect to lean on them harder in coming years, even though what they charge is rising. [12]

Why it matters — Every gene therapy and antibody in today's news is made somewhere, and increasingly that somewhere belongs to a company whose name is not on the box. [12]
20
A plan to run trials with AI at four stages

Clinical trials are slow and expensive, and much of the cost comes from finding patients, waiting years for hard results and working through complicated eligibility rules. [17] A review in Nature Reviews Bioengineering proposes running them with AI at four stages, from gathering and cleaning the patient data at the start to checking each AI tool against the exact job it is doing. It also sets out where regulators and ethics sit in that. [17]

Why it matters — It is a proposal rather than a result, and it names the awkward part plainly: an AI used in a trial has to be validated for the specific question it is asked. [17]
21
Tools that can write a whole gene in

Gene editing has moved from cutting DNA, which damages cells, to methods that change single letters without a cut. [19] Those handle small errors well and cannot insert a large piece of DNA. A review out this month covers the enzymes that can: recombinases and transposases, many of them found by searching genetic databases by computer and then improved in the laboratory. [19]

Why it matters — Diseases such as cystic fibrosis have hundreds of different causing mutations, and writing in one whole working gene would treat them all at once instead of one at a time. [19]
22
A four-year-old starts school after a transplant

Autumn, from Helperby in North Yorkshire, was diagnosed at 18 months with Hyper-IgE syndrome, a rare fault in the immune system that brings severe eczema and constant infections. [21] She had chemotherapy to clear out her own bone marrow, then a stem cell transplant from a donor in Germany in December, then more than 30 days in a hospital room that only her parents could enter. Six months of treatment in all. She started school on Tuesday. [21]

Why it matters — The treatment for the condition is to destroy a child's own immune system and rebuild it from a stranger's cells. [21]

02 Lesson why it matters

Why the same drug does more when it is given sooner

The drug is the same one already cleared for patients who had tried something else, and what changed this week is how early in the illness it may be given.

The twist

Moving a treatment earlier needs no new chemistry. It needs something that tells you the illness has started while the patient still feels perfectly well.

How it works

A disease runs as a sequence of steps
Each step leaves less that can be put back
Treated late, a drug has to undo damage as well as stop it
Treated early, it only has to stop the next step
So the same drug shows a bigger difference when it is given sooner
But acting early needs something that signals the disease has started

The same force, elsewhere today

Where this chain is also running, in today's other stories.

A boxed warning on last week's breast pill

The same step. The pill is given the moment a blood test finds the mutation, months before a scan would show the cancer growing again
Cancer-killing T cells grown from cord blood

The receptor goes into the blood stem cell before it becomes a T cell, so the receptors that would attack the patient never form and never have to be deleted
Chemotherapy's mark in children's healthy organs

The same chain read backwards. The mutations are written during treatment in childhood, and by the time a late illness appears there is nothing left to act on
A protein that leaks the brain's barrier

The leak is one of the first steps in Alzheimer's, so blocking fibronectin acts ahead of the plaques and tangles today's drugs are aimed at

Where you've seen this

Car brakes

pads changed when they squeak cost parts; left until they grind, they take the disc with them

Reading at school

a child helped in their first year needs a few hours; helped at fourteen they need years

A leaking roof

a slipped tile found in autumn is a tile; found in spring it is the ceiling as well

The catch

Treating earlier also means treating people who would never have got worse. And when the clock starts at the moment a test goes off, some of the extra months on paper come from starting the count sooner.

And the whole of it

Everybody here saw one slice of the chain. A regulator read 69 scans, a laboratory watched cells in a dish, a mother in North Yorkshire watched a four-year-old finish six months in hospital. The moment when acting helps most is usually the moment nobody can tell anything has begun.

03 Truth what's really going on

What is really going on

The US drug regulator cleared two cancer medicines this week without waiting to see whether patients live longer. Bayer's sevabertinib was cleared on 69 patients who all got the drug, with nobody to compare them against. [1] AstraZeneca's Etcamah was cleared on how long patients went before a scan showed the cancer growing, counted from the day a blood test found a mutation. [3] Both companies have to supply the survival evidence afterwards.

Why it works on us — A shrinking tumour can be measured within months and a longer life cannot, so the number that is ready first becomes the number the announcement is built on.

Who gains

Bayer — Its lung pill can now be sold to people at the start of the illness, a much larger group than those who have already tried something else. [1]
AstraZeneca — Its breast cancer pill was cleared on 4 September after both the regulator and its own outside advisers had reviewed the trial negatively. [4][2]
The firms that make medicines for other companies — The ten largest took $35.116bn in 2025, 6% more than the year before, and most drugmakers expect to lean on them harder. [12]
Revvity and Clean Cells — Both bought smaller specialists this week: Revvity a French grower of human pancreas cells, Clean Cells a firm that reads sequencing data. [9][11]
The companies that sell the tests — Etcamah may only be prescribed once an approved test has found an ESR1 mutation, so every prescription requires a test first. [3]

Who pays

Lung cancer patients who start on sevabertinib — They take a drug whose effect on survival nobody has measured, and whose label warns of diarrhoea, liver damage, lung inflammation, weakened heart pumping and eye problems. [1]
Patients prescribed Etcamah with ribociclib — The boxed warning says the pair raises the risk of a dangerous heart rhythm and of sudden death, and heart tracing is required before and during treatment. [3]
Novartis shareholders — The shares fell 11% in one day, wiping nearly $30bn and every gain the company had made since the start of the year. [5]
People who need cheaper versions of biological medicines — Nine in ten of the expensive biological drugs losing patent protection by 2034 have no lower-cost alternative being developed. [5]
Children who have had platinum chemotherapy — The drugs raised mutation levels in their healthy tissues to those normally seen in adults, and left a mark in the liver found in no other organ. [18]

What nobody knows yet

Open questions from across today’s stories — ours included.

01

Whether people given sevabertinib as their first treatment live longer than people given it later.

The regulator's notice reports only how many tumours shrank and for how long. There was no comparison group in the trial. [1]
02

How often Etcamah's heart-rhythm danger actually happens.

The label carries a boxed warning about irregular heartbeats and sudden death when the pill is taken with ribociclib, and gives no rate for it. [3]
03

Whether the mutations platinum chemotherapy leaves in children's healthy organs cause the illnesses those children get decades later.

The authors call it a plausible link. The study counted mutations; it did not follow anyone to a later disease. [18]
04

Whether lowering fibronectin helps a living person with Alzheimer's.

The work was done in donated brain tissue, in laboratory models of blood vessels and in animals. Nobody has given it to a patient. [6]
05

Whether the ready-made T cells grown from cord blood work in a human being.

They controlled ovarian cancer and melanoma in mice. Most things that work in mice do not work in people. [8]
06

What Novartis will do differently after losing 11% of its value in a day.

Eight shareholders said they will press the company on the companies it has bought, and Novartis has not said what it will change. [5]
07

Why nine in ten costly biological medicines losing patent protection by 2034 have no cheaper copy in development.

The figure comes from a report cited by the Wall Street Journal. The reasons behind it are not in the summary we could read. [5]
08

Whether Britain will clear sevabertinib for untreated patients too.

Britain's medicines regulator reviewed the same application alongside the US one under a scheme called Project Orbis, and its review is still running. [1]

04 Hope carry this

Autumn, who is four and lives in Helperby in North Yorkshire, started school on Tuesday. She was diagnosed at 18 months with Hyper-IgE syndrome, a fault in the immune system, and spent more than 30 days after a stem cell transplant in a hospital room that only her parents could enter.

Also true today

Children hospitalised with severe pneumonia in South Africa, Uganda, Zambia, Zimbabwe and Mozambique did as well on amoxicillin tablets as on five days of injections. Of 1,101 children aged two months to six years, 5.6% on tablets were readmitted or died within 28 days, against 6.3% on the drip alone.
Tumours shrank in 75% of 69 people whose lung cancer carried a fault in the HER2 gene and who had never been treated for it. Thirty-eight per cent of those responses were still going a year later.